Table 2.
Patient baseline and demographic characteristics according to treatment group and prior ablation in the ATHENA study
| Patients with ablation for AF/AFL | Patients with no ablation | |||
|---|---|---|---|---|
| Dronedarone (n = 90) | Placebo (n = 106) | Dronedarone (n = 2203) | Placebo (n = 2208) | |
| Age, mean years (SD) | 70.1 (9.1) | 68.2 (9.2) | 71.6 (8.9) | 71.8 (9.0) |
| Sex, male patients, n (%) | 57 (63.3) | 77 (72.6) | 1109 (50.3) | 1204 (54.5) |
| Race, n (%) | ||||
| White | 77 (85.6) | 96 (90.6) | 1982 (90.0) | 1965 (89.0) |
| Black | 3 (3.3) | 2 (1.9) | 16 (0.7) | 29 (1.3) |
| Asian | 7 (7.8) | 8 (7.5) | 141 (6.4) | 144 (6.5) |
| Other | 3 (3.3) | 0 (0) | 64 (2.9) | 70 (3.2) |
| Cardiovascular history, n (%) | ||||
| Hypertension | 76 (84.4) | 84 (79.2) | 1915 (86.9) | 1904 (86.2) |
| Structural heart disease | 56 (62.2) | 69 (65.1) | 1267a (58.0) | 1324b (60.6) |
| Tachycardia | 46 (51.1) | 56 (52.8) | 703 (31.9) | 731 (33.1) |
| Coronary heart disease | 26 (28.9) | 37 (34.9) | 631 (28.6) | 686 (31.1) |
| Non‐rheumatic valvular heart disease | 20 (22.2) | 20 (18.9) | 311 (14.1) | 330 (14.9) |
| Pacemaker | 23 (25.6) | 31 (29.2) | 188 (8.5) | 211 (9.6) |
| Lone AF | 3 (3.3) | 8 (7.5) | 137c (6.2) | 130c (5.9) |
| Ischemic dilated cardiomyopathy | 6 (6.7) | 11 (10.4) | 85 (3.9) | 106 (4.8) |
| Supraventricular tachycardia other than AF/AFL | 8 (8.9) | 7 (6.6) | 84 (3.8) | 79 (3.6) |
| Cardiac valve surgery | 9 (10.0) | 16 (15.1) | 71 (3.2) | 78 (3.5) |
| Non‐ischemic dilated cardiomyopathy | 5 (5.6) | 10 (9.4) | 77 (3.5) | 74 (3.4) |
| Hypertrophic cardiomyopathy | 5 (5.6) | 1 (0.9) | 38 (1.7) | 48 (2.2) |
| Implanted cardioverter defibrillator | 4 (4.4) | 11 (10.4) | 37 (1.7) | 31 (1.4) |
| Rheumatic valvular heart disease | 2 (2.2) | 5 (4.7) | 49 (2.2) | 24 (1.1) |
| Baseline cardiovascular examination, n (%) | ||||
| LVEF <35% | 5d (5.7) | 7 (6.6) | 87e (4.0) | 80f (3.7) |
| Chronic heart failure symptoms (NYHA Class ≥1) | 24 (26.7) | 23 (21.7) | 645 (29.3) | 666 (30.2) |
| Baseline medications, n (%) | ||||
| Beta blockers (except sotalol) | 66 (73.3) | 72 (67.9) | 1556 (70.6) | 1560 (70.7) |
| ACE/angiotensin II inhibitor | 56 (62.2) | 72 (67.9) | 1551 (70.4) | 1522 (68.9) |
| Oral anticoagulant | 69 (76.7) | 81 (76.4) | 1331 (60.4) | 1293 (58.6) |
| Low‐dose aspirin | 29 (32.2) | 41 (38.7) | 986 (44.8) | 972 (44.0) |
| Statin | 30 (33.3) | 52 (49.1) | 846 (38.4) | 857 (38.8) |
| Calcium antagonist with heart‐rate‐lowering effect | 17 (18.9) | 18 (17.0) | 314 (14.3) | 286 (13.0) |
| Digitalis | 17 (18.9) | 18 (17.0) | 304 (13.8) | 287 (13.0) |
Note: Denominators for calculation of percentages; an = 2184; bn = 2185; cn = 2199; dn = 87; en = 2169; fn = 2162.
Abbreviations: ACE, angiotensin‐converting enzyme; AF, atrial fibrillation; AFL, atrial flutter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.